Phase I/II Study to Evaluate the Safety and Efficacy of an Ovarian Cancer Vaccine Therapy
Learn More About This Topic: Chat with Us | Email Us
Summary
This phase I/II study, reviewed and cleared by the U.S. Food and Drug Administration (FDA) in April 2008, evaluates the safety and efficacy of a unique ovarian cancer vaccine therapy for patients with recurrent and chemotherapy-resistant, late stage disease. CTCA patients undergoing treatment for stage III or IV ovarian cancer who have tumor progression, despite at least one, but no more than two chemotherapy regimens, may be eligible to participate in the study based on specific criteria. Participants must first undergo surgery and intraperitoneal chemotherapy at CTCA at Midwestern Regional Medical Center. CTCA will then work with AVAX Technologies, Inc. to create a personalized vaccine, using each patient’s tumor cells which have been surgically removed at CTCA at Midwestern Regional Medical Center. These cells will be modified in the AVAX laboratories and designed to produce an immunologic response to treat the patient’s ovarian cancer. Patients become eligible for the vaccine trial when it is determined that enough tumor cells exist to create the vaccine.
For More Information:
Please contact one of our Oncology Information Specialists at 1-800-615-3055 to learn more about this clinical trial. Oncology Information Specialists are available 24 hours a day, 7 days a week, 365 days a year.